



Universiteit
Leiden
The Netherlands

Immune evasion by varicelloviruses : the identification of a new family of TAP-inhibiting proteins

Koppers-Lalić, D.

Citation

Koppers-Lalić, D. (2007, September 11). *Immune evasion by varicelloviruses : the identification of a new family of TAP-inhibiting proteins*. Retrieved from <https://hdl.handle.net/1887/12381>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/12381>

Note: To cite this publication please use the final published version (if applicable).

CHAPTER

7

Submitted

TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major Histocompatibility antigen-specific recognition by cytotoxic T lymphocytes

Liesbeth E.M. Oosten¹, Danijela Koppers-Lalić², Els Blokland¹, Arend Mulder¹, Maaïke E. Rensing², Tuna Mutis^{1,3}, Astrid G.S. van Halteren¹, Emmanuel J. H. J. Wiertz¹ and Els Goulmy¹

¹ Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands;

² Department of Medical Microbiology, Leiden University Medical Center, 2300 RC, Leiden, The Netherlands;

³ Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands

Cytotoxic T lymphocytes (CTLs) recognizing hematopoietic system-specific minor Histocompatibility antigens (mHags) are candidate reagents for adoptive immunotherapy after allogeneic stem cell transplantation. CTLs specific for mHags that are restricted by non-self 'allo' HLA molecules could be used for adoptive immunotherapy after HLA-mismatched stem cell transplantation. The generation of mHag-specific alloHLA-restricted CTLs requires antigen-presenting cells (APCs) expressing low numbers of endogenous peptides to avoid co-induction of undesired alloHLA-reactivities. In this study we exploited viral evasion strategies to generate APCs expressing a controlled set of endogenous peptides. Herpesviruses persist lifelong following primary infection due to expression of viral gene products that hamper T cell recognition of infected cells. The herpesvirus-derived proteins US6, ICP47 and UL49.5 downregulate endogenous antigen-presentation in human APCs via inhibition of the transporter associated with antigen-processing (TAP). Epstein-Barr virus-transformed B cell lines transduced with retroviral vectors encoding US6, ICP47, or UL49.5 exhibited a stable decrease in cell surface HLA class I expression and were protected from lysis by mHag-specific CTLs. Exogenous addition of mHag-peptide fully restored target cell recognition. UL49.5 showed the most pronounced inhibitory effect, reducing HLA class I expression and mHag-specific lysis up to 99%. UL49.5 also significantly diminished alloHLA-reactivities mediated by alloHLA-specific CTLs. In conclusion, UL49.5 could be a powerful new tool to study and modulate endogenous antigen-presentation.

7

Cytotoxic T lymphocytes (CTLs) specific for the minor Histocompatibility antigens (mHags) HA-1 or HA-2 are potent reagents for adoptive immunotherapy of leukemia after allogeneic HLA-matched mHag-mismatched stem cell transplantation (SCT) (1). CTL responses directed against HA-1 and HA-2 are specific for hematopoietic system-derived cells including leukemic cells and their progenitors (2-5). mHag-specific CTLs can be generated *in vitro* using peptide-pulsed or mHag-transduced autologous dendritic cells (DCs) (6;7). CTLs can also be targeted to mHags presented in the context of non-self 'allo' HLA molecules by the use of allogeneic HLA-mismatched antigen-presenting cells (APCs) (8). These CTLs may serve as reagents for the treatment of relapsed leukemia after HLA-mismatched SCT. However, the generation of mHag-specific alloHLA-A2-restricted CTLs is hampered by adventitious expansion of broad alloHLA-A2-specific T cells present in the T cell repertoire of HLA-A^{2neg} individuals (8). Such alloHLA-reactive T cells are directed at a variety of endogenous peptides presented by alloHLA molecules (9) and are potentially harmful to the patient. Minimizing the number of peptides presented by the allogeneic APC may reduce the induction of undesired alloHLA-reactivities.

Endogenous peptide-presentation is affected by inhibition of the transporter associated with antigen-processing (TAP). TAP transports cytosolic peptides into the endoplasmatic reticulum (ER) (10), where they are loaded onto HLA class I molecules linked to TAP through tapasin (11). In the absence of functional TAP, most HLA class I molecules are not loaded with peptides and are eventually redirected to the cytosol where they are degraded by proteasomes (12-14). Consequently, HLA class I molecules on the cell surface of a TAP-deficient cell will present only a limited number of signal sequence-derived peptides that can serve as ligands for alloHLA-reactive T cells (15). Exogenous addition of peptides stabilizes these HLA class I molecules, thereby restoring antigen-presentation in a peptide-specific manner (16;17). A TAP-inhibited allogeneic APC that has been exogenously loaded with the peptide of choice may retain the capacity to stimulate CTLs specific for the added peptide, without adventitious co-stimulation of CTLs specific for other endogenous peptides. We aimed at investigating whether HLA-A2^{pos} APCs, transduced with a TAP-inhibiting protein and pulsed with mHag peptides, can indeed elicit mHag-specific but not alloHLA-specific CTL responses. If so, such APCs would be suitable antigen-specific stimulators for the in vitro induction of mHag-specific alloHLA-A2-restricted T cells.

Three different proteins have been described so far that specifically inhibit peptide translocation by TAP in human cells. The human cytomegalovirus-encoded US6 is an ER-resident protein that blocks conformational changes within the transporter complex required for adenosine triphosphate-binding and thus peptide-translocation (18;19). ICP47 is a herpes simplex virus type 1- and type 2 -encoded protein that associates with cytosolic domains of the TAP-complex, thereby acting as a high-affinity competitor for peptide-binding (20-23). Recently, the UL49.5 protein encoded by the bovine herpesvirus type 1 has been identified as a potent inhibitor of TAP (24). UL49.5 inactivates TAP by arresting the transporter in a translocation-incompetent conformation and mediating its degradation by proteasomes.

We investigated these three TAP-inhibitors for their individual capacity to block endogenous antigen-presentation by APCs. To this end, we transduced Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCLs) with retroviral vectors encoding US6, ICP47 or UL49.5. The effects of these viral TAP-inhibitors on cell surface HLA class I expression and on functional HLA/peptide ligand recognition by mHag-specific and alloHLA-specific CTL clones were analyzed.

Materials and Methods

Retroviral Constructs cDNA's encoding the viral proteins US6, ICP47 and UL49.5 were generated by PCR under standard conditions. Plasmids containing the US6 and ICP47 genes were kind gifts of Prof. J. Neefjes (Dutch Cancer Institute, Amsterdam) and Dr. K. Früh (Vaccine and Gene Therapy Institute, Oregon Health and Science University), respectively. The PCR-generated products were inserted into the pLZRS-polylinker-IRES-eGFP retroviral vector (http://www.stanford.edu/group/nolan/protocols/pro_helper_free.html) upstream of the internal ribosomal entry site (IRES) and enhanced green fluorescent protein (GFP). Retrovirus production and transduction of EBV-LCL were performed as described (http://www.stanford.edu/group/nolan/protocols/pro_helper_free.html).

Cell lines EBV-LCLs Modo and Hodo (Table 1) were transduced with retroviral vectors to generate the following stable GFP-positive cell lines: Modo-control and Hodo-control (containing a retroviral vector without insert); Modo-US6; Modo-ICP47; Modo-UL49.5 and Hodo-UL49.5. GFP-positive cells were selected by a FACS Vantage cell sorter (Becton Dickinson, San Jose, CA, USA) to ensure homogenous and comparable expression of the various TAP-inhibitors. All EBV-LCLs were cultured in Iscove's Modified Dulbecco's Medium

(IMDM) containing 5% fetal bovine serum.

In vitro generation of mHag- and alloHLA-specific CTL clones is documented in detail elsewhere (25;26). Clone #1 was kindly donated by Prof. J.H.F. Falkenburg (Leiden University Medical Center). All CTL clones were cultured in IMDM containing 10% pooled human serum and 25 U/ml interleukin-2 (Cetus, Emeryville, CA, USA).

Table 1. HLA class I and mHag phenotyping of the EBV-LCLs used in this study

EBV-LCLs	HLA-A	HLA-B	HLA-C	mHags		
Modo	A2	B44, B60	C5, C10	HY	HA-1	HA-2
Hodo	A1, A11	B8, B60	C3, C7	HY	-	-
H6	A2	B27, B62	C1, C3	-	-	-
T2	A2	B51	C2	-	HA-1	HA-2

Synthetic peptides and human monoclonal antibodies HA-1, HA-2 and HY peptides were synthesized according to their reported sequences (27-29). Where stated, EBV-LCLs were pulsed with 10 µg/ml of relevant mHag peptides for 1 hour at 37°C.

Hybridomas producing human monoclonal antibodies (mAbs) SN607D8 (anti HLA-A2/A28), VTM1F11 (anti HLA-B7/B27/B60) and GV5D1 (anti HLA-A1/A9) were generated as described previously (30). The HLA-specificities of these mAbs (all IgG) were determined by complement-mediated cytotoxicity assays against large (n>240) panels of serologically typed peripheral blood mononuclear cells. The mAbs were purified by protein A chromatography (Pharmacia, Uppsala, Sweden) and biotin-labeled (Pierce, Rockford, IL, USA) following manufacturers' instructions. The reactivities of biotin-labelled mAbs were validated by flowcytometry. All biotin-conjugated mAbs showed homogeneous, HLA-allele-specific staining on CD3 positive cells.

Flowcytometric analyses HLA class I cell surface expression was determined by labeling with biotinylated human HLA-specific mAbs counterstained with streptavidin-phycoerythrin (Becton Dickinson) in appropriate dilutions. Gates were set on vital lymphocytes according to their typical forward- and side-scattering characteristics. All flowcytometric analyses were performed on a FACSCalibur with CellQuest software (Becton Dickinson). Results are displayed as mean fluorescence intensity (MFI).

Cytotoxicity assays Cytotoxicity was evaluated by incubating 2500 ⁵¹Cr labeled target cells with serial dilutions of CTLs for 4 hours. Supernatants were harvested for gamma counting. % specific lysis = (experimental release-spontaneous release)/(maximal release-spontaneous release) x 100%. Results are expressed as the mean of duplicate samples and shown for an effector:target (E:T) ratio of 10:1 unless stated otherwise.

Statistics Statistical analyses were performed using unpaired t-tests for data derived from single experiments and paired t-tests for data pooled from multiple experiments. P values < 0.05 were considered to be significant. Data pooled from multiple experiments were standardized as follows. Fluorescence (in fluorescence units): (mean fluorescence – mean fluorescence of isotype control) / (mean fluorescence of mock control – mean fluorescence of isotype control); values are expressed as percentages. Lysis: mean % lysis / mean % lysis mock. Error bars represent standard errors of the mean.

Results

Effects of US6, ICP47 and UL49.5 on HLA class I cell surface levels EBV-LCLs derived from HLA-A2^{pos}, HLA-B60^{pos} donor Modo (Table I), were retrovirally transduced with US6, ICP47 or UL49.5, or with an empty control vector to evaluate the effects of the three TAP-inhibitors on HLA class I expression and antigen-presentation. Cell surface levels of HLA-A2 and HLA-B60 were analyzed using HLA allele-specific mAbs (Figure 1A, B). The HLA-A2 expression of EBV-LCLs transduced with US6, ICP47 or UL49.5 decreased with 63%, 57% and 73% respectively; the HLA-B60 expression with 80%, 82% and 99% respectively, compared to the empty vector-transduced EBV-LCL ($P < 0.05$). These low HLA class I cell surface levels remained consistent upon continuous *in vitro* culture (data not shown). No difference in HLA-A2 or HLA-B60 expression could be observed between untransduced and empty vector-transduced EBV-LCLs.




Fig. 1. HLA-A2 and HLA-B60 expression by TAP-inhibitor transduced EBV-LCLs (A) Cell surface expression of HLA-A2 (upper series) and HLA-B60 (lower series) by Modo EBV-LCLs that are untransduced, transduced with an empty vector (control), or transduced with the viral TAP-inhibitors US6, ICP47 or UL49.5. X-axis shows GFP-expression. (B) Mean cell surface expression of HLA-A2 and HLA-B60 by the untransduced and transduced Modo EBV-LCLs.

Effects of US6, ICP47 and UL49.5 on mHag-specific target cell recognition. To determine whether the downregulation of HLA class I cell surface expression resulted in a decrement of functional recognition by mHag-specific CTLs, the transduced Modo EBV-LCLs were used as target cells in cytotoxicity assays. Four different CTL clones with previously established specificity for the mHags (HLA-) A2/HA-1, A2/HA-2, A2/HY, or B60/HY, were used as effector T cells (Figure 2A). The Modo EBV-LCLs naturally express each of these mHags




Fig. 2. mHag-specific lysis of TAP-inhibitor transduced EBV-LCLs (A) mHag-specific lysis of untransduced, empty vector (control)-transduced or US6-, ICP47- or UL49.5-transduced Modo EBV-LCLs by four different CTL clones specific for A2/HA-1, A2/HA-2, A2/HY or B60/HY. (B) Effect of increasing effector:target (E:T) ratios on mHag-specific lysis of empty vector- (control), US6-, ICP47- or UL49.5-transduced Modo EBV-LCLs by an A2/HA-1-specific CTL clone.

(Table 1). All CTL clones exhibited a significantly diminished recognition of TAP-inhibitor-transduced EBV-LCLs as compared to empty vector-transduced EBV-LCL ($P < 0.05$). Inhibition of target cell lysis ranged from 70% to 87% for US6, 77% to 89% for ICP47, and 85% to 99% for UL49.5 for the various CTL clones. Increasing the E:T ratio did not restore target cell recognition (Figure 2B), indicating consistent blocking of endogenous mHag-peptide translocation and HLA-loading by TAP-inhibitors. No difference could be detected between untransduced and control-transduced EBV-LCLs for any of the CTL clones tested.

TAP-inhibiting effects by US6, ICP47, and UL49.5 were statistically analyzed by pooling the data on HLA-A2 and HLA-B60 expression as well as the data on mHag-recognition by the various CTL clones from the experiments described above. This analysis showed significant differences for decrement of HLA class I expression between US6 and UL49.5 ($P=0.0264$), and ICP47 and UL49.5 ($P=0.0006$), but not between US6 and ICP47 ($P=0.6474$). Similarly, decreases in mHag-specific lysis differed significantly between US6 and UL49.5 ($P=0.0005$), and ICP47 and UL49.5 ($P=0.0346$), but not between US6 and ICP47 ($P=0.1355$). These results indicate that UL49.5 is consistently more effective in downregulating endogenous mHag-presentation.

Effects of exogenous peptide-addition on recognition of TAP-inhibited target cells.

TAP inhibitory proteins affect HLA class I expression because the absence of endogenous peptide renders cell surface HLA class I molecules unstable. Yet, HLA class I cell surface expression is not completely abrogated. Exogenously added peptides can bind to these HLA class I molecules. To investigate whether sufficient HLA class I molecules remain for functional mHag presentation, we loaded TAP-inhibitor transduced EBV-LCLs with mHag peptides. Hereto, HLA-A2^{pos} HA-1^{pos} Modo EBV-LCLs transduced with US6, ICP47, UL49.5, or an empty vector, were pulsed with various concentrations of HA-1 peptide. An EBV-LCL derived from HLA-A2^{pos} HA-1^{neg} donor H6 (Table I) was included as a control (Figure 3). Addition of HA-1




Fig. 3. Lysis of TAP-inhibitor transduced EBV-LCLs pulsed with peptide. Effect of exogenous addition of HA-1 peptide on HA-1-specific lysis of empty vector- (control), US6-, ICP47- or UL49.5-transduced Modo EBV-LCLs and HLA-A2^{pos} mHag^{neg} H6 EBV-LCLs by a A2/HA-1-specific CTL clone.

peptide to TAP-inhibited EBV-LCLs restored recognition by A2/HA-1-specific CTLs in a dose-dependent manner to the level observed for the control target cell H6. Addition of non-specific peptide had no effect (data not shown). Thus, even low numbers of HLA molecules appear to be sufficient for functional mHag-specific recognition; an observation in line with the functional recognition of low copy numbers of mHags (1). Thus, upon functional inhibition of TAP, the target cell can still be pulsed exogenously with any HLA-binding peptide of interest; one of the original aims of our study.

Effects of TAP-inhibition on alloHLA-A2 -specific target cell recognition. As mentioned above, TAP-inhibition does not abrogate cell surface HLA class I expression completely. Thus, TAP-inhibited EBV-LCLs may still present peptides on the cell surface that might be recognized by alloHLA-specific CTLs. To test the latter proposition, we compared alloHLA-recognition of empty vector-transduced EBV-LCL and TAP-inhibited EBV-LCLs. EBV-LCLs derived from HLA-A2^{pos} donor Modo and transduced with US6, ICP47, UL49.5 or with an empty vector were used as targets in a cytotoxicity assay. As effector T cells, we used two alloHLA-A2 specific CTL clones (designated clone #1 and clone #2). Clone #1 was shown to be TAP-dependent in earlier experiments (data not shown), whereas clone #2 is known to be TAP-independent (31). The HLA-A2^{pos} TAP-deficient cell line T2 was included as a control. Two E:T ratios are shown for the transduced Modo EBV-LCLs i.e. 10:1 and 1:1 (Figure 4).




Fig. 4. Lysis of TAP-inhibitor transduced EBV-LCLs by alloHLA-A2-specific CTL clones. AlloHLA-A2-specific lysis of untransduced, empty vector (control) -transduced, US6, ICP47 or UL49.5-transduced Modo EBV-LCLs, and T2 cells, by alloHLA-A2-specific CTL clones #1 and #2. Transduced Modo light grey bars show an additional E:T ratio of 1:1.

TAP-dependent CTL clone #1 exhibited a significantly diminished recognition of ICP47- and UL49.5-transduced EBV-LCLs as compared to empty vector-transduced EBV-LCL for both E:T ratios ($P < 0.05$). No significant inhibition of lysis was observed for US6 in this experiment ($P = 0.05$). Of ICP47 and UL49.5, the latter was again the more potent inhibitor ($P < 0.05$ E:T 1:1, $P = 0.33$ E:T 10:1). AlloHLA-A2 recognition of UL49.5-transduced Modo EBV-LCL was reduced

by 90% for E:T ratio 1:1 but only by 47% for E:T ratio 10:1. In comparison, at E:T ratio 10:1 mHag-specific recognition of UL49.5-transduced MODO-EBV-LCLs was abrogated almost completely (Figure 2A). Apparently, UL49.5 does not inhibit the presentation of peptides recognized by TAP-dependent alloHLA-A2-specific CTLs completely. AlloHLA-A2 recognition by TAP-independent CTL clone #2 was not affected by any of the TAP-inhibitors.

Effects of UL49.5 on alloHLA-A1-specific target cell recognition. Inhibition of TAP has a stronger effect on HLA-A1-expression than on HLA-A2-expression (32;33). Therefore, we also evaluated alloHLA-A1-specific recognition of UL49.5-transduced EBV-LCLs. To that end, we retrovirally transduced EBV-LCLs derived from HLA-A1^{pos} donor Hodo with UL49.5 or with an empty control vector. UL49.5-transduced Hodo EBV-LCL showed significantly decreased cell surface HLA-A1 expression ($P < 0.05$) and decreased susceptibility to lysis by an HLA-A1-restricted HY-specific CTL clone (data not shown). UL49.5- and control-transduced Hodo EBV-LCLs were then used as targets for an alloHLA-A1-specific CTL clone (designated clone #3) as effector cell. E:T ratios 10:1 and 1:1 are shown for the transduced Hodo EBV-LCLs (Figure 5). AlloHLA-A1-specific recognition was significantly decreased for UL49.5-expressing Hodo EBV-LCLs as compared to control-transduced EBV-LCLs ($P < 0.05$). However, downregulation of alloHLA-A1-specific lysis was not complete, similar to that of alloHLA-A2-specific lysis (Figure 4). Taken together, these findings indicate that retroviral transduction of APCs with UL49.5 diminishes but not abrogates major alloHLA-recognition in a TAP-dependent fashion.




Fig. 5. Lysis of UL49.5 transduced EBV-LCLs by alloHLA-specific CTL clones. Left panel: mean cell surface expression of HLA-A1 by Hodo EBV-LCLs. Right panel: alloHLA-A1-specific lysis of untransduced, empty vector (control) -transduced, or UL49.5-transduced Hodo EBV-LCLs, and T2 cells, by alloHLA-A1-specific CTL clone #3. Transduced Hodo light grey bars show an additional E:T ratio of 1:1.

Discussion

In this study, we investigated the capacity of three virus-derived proteins that specifically inhibit peptide-translocation by TAP, to block minor and major Histocompatibility antigen-specific recognition. Our results show that mHag^{pos} EBV-LCLs transduced with retroviral vectors encoding US6, ICP47 or UL49.5 all exhibit a stable decrease in cell surface HLA class I expression and are protected from lysis by mHag-specific CTL clones. Antigen-presentation can be fully restored by exogenous addition of specific mHag peptides, demonstrating that cells transduced with viral TAP-inhibitors can be used as functional APCs. Transduction of EBV-LCLs with TAP-inhibitors also inhibits alloHLA-A1 and alloHLA-A2-specific recognition, albeit to a lesser extent than mHag-specific recognition. Herewith our scientific challenge to modify the peptide repertoire of a particular APC using viral TAP-inhibitors, thereby creating an opportunity to direct the CTL response towards defined, e.g. tumor-associated specificities, is verified.

From the three TAP-inhibitors we analyzed, UL49.5 is the most potent. It reduces mHag-specific lysis of EBV-LCLs to the level observed for the TAP-deficient cell line T2 (data not shown). Whereas US6 blocks conformational changes required for ATP-binding and peptide translocation (10) and ICP47 competes for peptide binding (13), UL49.5 inhibits essential conformational changes at a later phase of the translocation cycle, thereby fully blocking the transport of peptide. In addition, UL49.5 targets TAP for proteasomal degradation causing disintegration of the MHC class I peptide loading complex (12;32;33), a phenomenon not observed for US6 or (19;21-24). UL49.5's "double strike policy" ensures optimal downregulation of TAP and thus better protection from the host immune response against the virus encoding this protein.

Earlier studies have investigated the effect of TAP-inhibition by ICP47 on alloHLA-recognition and reported decreased lysis of ICP47-transduced target cells by sensitized lymphocytes (34;35). We are the first to look at the effect of TAP-inhibition on alloHLA-recognition at a clonal level. The alloHLA-A1- and alloHLA-A2-specific CTL clones used in this study recognize as yet undefined endogenous peptides that associate with HLA-A1 or HLA-A2 (25;36). AlloHLA-A2-specific CTL clone #1 does not lyse HLA-A2^{pos} TAP-deficient cell line T2, but does lyse T2 reconstituted with TAP (data not shown). These data imply that cell surface expression of the peptide recognized by clone #1 is dependent on the presence of functional TAP. Yet, recognition of an HLA-A2^{pos} EBV-LCL transduced with UL49.5 by clone #1 is only partially inhibited, while recognition of the same EBV-LCL by a mHag-specific CTL clone is almost completely abrogated.

There are several possible explanations for this observation. First, TAP-inhibition by UL49.5 gene transfer may not be complete. If CTL clone #1 expresses a TCR of high affinity, a very low peptide-copy number per cell will be sufficient to trigger a lytic response. Alternatively, if the peptide recognized by CTL clone #1 is present at a greater peptide-copy number per cell or displays a greater affinity for the TAP-transporter than mHag-derived peptides, its presentation may be relatively preserved in a TAP-inhibited, but not completely blocked setting. Assuming that TAP-inhibition by UL49.5 gene transfer is complete, the continuous presence of peptide recognized by CTL clone #1 could be explained by an alternative route of antigen-presentation. Lautscham et al. showed recently that hydrophobic peptides may be processed via a proteasome-dependent, TAP-independent pathway (37). Peptides of intermediate hydrophobicity that were normally TAP-dependent showed inappropriate presentation in TAP-negative cells when expressed by minigenes (38). The partial inhibition of alloHLA-A2-specific lysis by CTL clone #1 as compared to a near complete arrest of mHag-specific lysis could thus be the result of differences in hydrophobicity between the relevant peptides.

Because inhibition of alloHLA-recognition by UL49.5 is incomplete, our original aim of generating antigen-specific stimulators for the induction of mHag-specific alloHLA-restricted

T cells is not achieved. Yet, we do show that UL49.5 effectively abrogates CTL recognition of relevant target cells and that addition of a chosen peptide efficiently restores peptide-specific CTL recognition. UL49.5 thus facilitates preferential presentation of a target sequence, enabling the direction of CTL responses towards a desired target epitope. These observations could offer interesting new possibilities for immunomodulation.

The results of our study are relevant to other areas of research as well. First, UL49.5 may be helpful in elucidating the “alloresponses” that still hamper SCT across HLA barriers. Studies of the “allopeptides” recognized by alloHLA-specific CTLs are complicated by two factors. The number of potential ligands is large, because the alloHLA-specific CTL repertoire has not been selected to ignore self-peptides presented by alloHLA-molecules. In addition, CTLs specific for viral peptides bound by self-HLA molecules have been shown to exhibit crossreactivity with alloHLA molecules, rendering the precise target antigen difficult to establish (39). Several known human CMV-encoded proteins block cell surface expression of HLA class I molecules completely (40). US3 retains HLA class I molecules in the ER (41;42), while US2 and US11 target HLA class I allele heavy chains for degradation in the cytosol (14;43). Each of these proteins affects a defined set of HLA class I alleles (42;44;45). The characteristics of US3, US2, and US11 can therefore be used to abrogate antigen-presentation and thus crossreactive T cell recognition for a selected set of HLA class I alleles expressed by a particular APC. The peptide repertoire presented by the remaining HLA alleles can then be modified by UL49.5. Thus, US2, US3, and US11 together with UL49.5 constitute a powerful viral toolbox facilitating studies of allopeptides’ recognition patterns.

Second, impairment of TAP, and thus of antigen-presentation, is frequently observed in human tumors (46), allowing tumors to escape from immune surveillance by CTLs (47;48). Recently, it was shown that an alternative repertoire of peptide epitopes emerges at the surface of murine cells with impaired function of TAP (49). These peptides most likely derive from the ER but are not normally loaded into MHC class I due to the presence of more abundant TAP-dependent peptides. Because they are absent on normal cells, these “new” peptides may act as immunogenic neo-antigens and can be exploited as targets for immunotherapy against TAP-deficient tumors. The potent TAP inhibitor UL49.5 might be used to elicit the presentation of these peptide epitopes and aid the study of the TAP-independent peptide-repertoires of human tumor cells.

In summary, we here show novel functional characteristics of the recently described varicellovirus-derived TAP-inhibitor UL49.5. UL49.5 downregulates HLA class I expression and inhibits mHag-specific CTL responses more efficiently than US6 and ICP47. UL49.5 also reduces alloHLA-reactivity, thus providing a new tool to study fundamental aspects of alloHLA-reactivity in general and the TAP-dependent and -independent peptide-repertoires in particular.

Acknowledgements

We would like to thank Mr. J. van Voorden, Ms. D. van Leeuwen and Ms. C. Eijsink (Leiden University Medical Center) for their technical assistance, Dr. F. Momburg (German Cancer Research Center, Germany) for providing valuable reagents and Prof. J.H.F. Falkenburg (Leiden University Medical Center) for critical reading. This work was funded in part by grants from the Dutch Cancer Society, the Leukemia & Lymphoma Society and the Dutch Diabetes Research Foundation (to D.K-L).

References

1. **Goulmy E** (1997) Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. *Immunol Rev* 157:125-140.
2. **Wilke M, Dolstra H, Maas F, Pool J, Brouwer R, Falkenburg JHF, Rebello A, Lamers F, Schuurin E, Kluin P, Brasseur F, Goulmy E** (2003) Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies. *Hematol J* 4:315-320.
3. **van der Harst D, Goulmy E, Falkenburg JHF, Kooij-Winkelaar YM, Luxemburg-Heijs SA, Goselink HM, Brand A** (1994) Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. *Blood* 83:1060-1066.
4. **de Bueger M, Bakker A, van Rood JJ, van der Woude F, Goulmy E** (1992) Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. *J Immunol* 149:1788-1794.
5. **Falkenburg JHF, Goselink HM, van der Harst D, Luxemburg-Heijs SA, Kooy-Winkelaar YM, Faber LM, de Kroon J, Brand A, Fibbe WE, Willemze R, Goulmy E** (1991) Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. *J Exp Med* 174:27-33.
6. **Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E** (1999) Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. *Blood* 93:2336-2341.
7. **Gillespie G, Mutis T, Schrama E, Kamp J, Esendam B, Falkenburg JHF, Goulmy E, Moss P** (2000) HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand. *Hematol J* 1:403-410.
8. **Mutis T, Blokland E, Kester M, Schrama E, Goulmy E** (2002) Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. *Blood* 100:547-552.
9. **Whitelegg AM, Oosten LEM, Jordan S, Kester M, van Halteren AGS, Madrigal JA, Goulmy E, Barber LD** (2005) Investigation of Peptide Involvement in T Cell Allorecognition Using Recombinant HLA Class I Multimers. *J Immunol* 175:1706-1714.
10. **Abele R, Tampe R** (2004) The ABCs of immunology: structure and function of TAP, the transporter associated with antigen processing. *Physiology* 19:216-224.
11. **Ortmann B, Copeman J, Lehner PJ, Sadasivan B, Herberg JA, Grandea AG, Riddell SR, Tampe R, Spies T, Trowsdale J, Cresswell P** (1997) A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. *Science* 277:1306-1309.
12. **Townsend A, Ohlen C, Bastin J, Ljunggren HG, Foster L, Karre K** (1989) Association of class I major histocompatibility heavy and light chains induced by viral peptides. *Nature* 340:443-448.
13. **Hughes EA, Hammond C, Cresswell P** (1997) Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. *Proc Natl Acad Sci USA* 94:1896-1901.
14. **Wiertz EJ, Tortorella D, Bogoy M, Yu J, Mothes W, Jones TR, Rapoport TA, Ploegh HL** (1996) Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. *Nature* 384:432-438.
15. **Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, Engelhard VH** (1992) HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. *Science* 255:1264-1266.
16. **Stuber G, Modrow S, Hoglund P, Franksson L, Elvin J, Wolf H, Karre K, Klein G** (1992) Assessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loading-deficient cells. *Eur J Immunol* 22:2697-2703.
17. **Gatfield J, Lammert E, Nikolaus P, Munz C, Rothenfusser S, Fisch P, Stevanovic S, Schild H, Rammensee H-G, Arnold D** (1998) Cell lines transfected with the TAP inhibitor ICP47 allow testing peptide binding to a variety of HLA class I molecules. *Int Immunol* 10:1665-1672.
18. **Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL, Peterson PA, Yang Y, Fruh K** (1997) The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. *Immunity* 6:613-621.

19. **Lehner PJ, Karttunen JT, Wilkinson GW, Cresswell P** (1997) The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. *Proc Natl Acad Sci USA* 94:6904-6909.
20. **Neumann L, Kraas W, Uebel S, Jung G, Tampe R** (1997) The active domain of the herpes simplex virus protein ICP47: a potent inhibitor of the transporter associated with antigen processing. *J Mol Biol* 272:484-492.
21. **Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh HL, Johnson D** (1995) Herpes simplex virus turns off the TAP to evade host immunity. *Nature* 375:411-415.
22. **Tomazin R, Hill AB, Jugovic P, York I, van Ender P, Ploegh HL, Andrews DW, Johnson DC** (1996) Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. *EMBO J* 15:3256-3266.
23. **Ahn K, Meyer TH, Uebel S, Sempe P, Djaballah H, Yang Y, Peterson PA, Fruh K, Tampe R** (1996) Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. *EMBO J* 15:3247-3255.
24. **Koppers-Lalić D, Reits EA, Rensing ME, Lipińska AD, Abele R, Koch J, Rezende MM, Admiraal P, van Leeuwen D, Biernowska-Szewczyk K, Mettenleiter TC, Rijsewijk FA, Tampe R, Neeffjes J, Wiertz EJ** (2005) Varicelloviruses avoid T cell recognition by UL49.5-mediated inactivation of the transporter associated with antigen processing. *Proc Natl Acad Sci USA* 102:5144-5149.
25. **Heemskerk MH, de Paus RA, Lurvink EG, Koning F, Mulder A, Willemze R, van Rood JJ, Falkenburg JHF** (2001) Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. *Proc Natl Acad Sci USA* 98:6806-6811.
26. **Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E** (1999) Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. *Blood* 93:2336-2341.
27. **den Haan JM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL, Reinhardus C, Shabanowitz J, Offringa R, Hunt DF, Engelhard VH, Goulmy E** (1998) The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. *Science* 279:1054-1057.
28. **den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, Skipper J, Shabanowitz J, Hunt DF, Engelhard VH, Goulmy E** (1995) Identification of a graft versus host disease-associated human minor histocompatibility antigen. *Science* 268:1476-1480.
29. **Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y, Blokland E, Shabanowitz J, Agulnik AI, Hendrickson RC, Bishop CE, Hunt DF, Goulmy E, Engelhard VH** (1995) Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. *Science* 269:1588-1590.
30. **Mulder A, Kardol M, Regan J, Buelow R, Claas F** (1997) Reactivity of twenty-two cytotoxic human monoclonal HLA antibodies towards soluble HLA class I in an enzyme-linked immunosorbent assay (PRA-STAT). *Hum Immunol* 56:106-113.
31. **Momburg F, Ortiz-Navarrete V, Neeffjes J, Goulmy E, van de Wal Y, Spits H, Powis SJ, Butcher GW, Howard JC, Walden P, Hammerling GJ** (1992) Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. *Nature* 360:174-177.
32. **Grande AG III, Lehner PJ, Cresswell P, Spies T** (1997) Regulation of MHC class I heterodimer stability and interaction with TAP by tapasin. *Immunogenetics* 46:477-483.
33. **Lewis JW, Sewell A, Price D, Elliott T** (1998) HLA-A*0201 presents TAP-dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin. *Eur J Immunol* 28:3214-3220.
34. **Furukawa L, Brevetti LS, Brady SE, Johnson D, Ma M, Welling TH, Messina LM** (2000) Adenoviral-mediated gene transfer of ICP47 inhibits major histocompatibility complex class I expression on vascular cells in vitro. *J Vasc Surg* 31:558-566.
35. **Radosevich TJ, Seregina T, Link CJ** (2003) Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon-gamma exposure. *Hum Gene Ther* 14:1765-1775.
36. **Horai S, van der Poel JJ, Goulmy E** (1982) Differential recognition of the serologically defined HLA-A2 antigen by allogeneic cytotoxic T cells. I. Population studies. *Immunogenetics* 16:135-142.
37. **Lautscham G, Rickinson A, Blake N** (2003) TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus. *Microbes Infect* 5:291-299.
38. **Lautscham G, Mayrhofer S, Taylor G, Haigh T, Leese A, Rickinson A, Blake N** (2001) Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. *J Exp Med* 194:1053-1068.

39. **Burrows SR, Khanna R, Silins SL, Moss DJ** (1999) The influence of antiviral T-cell responses on the alloreactive repertoire. *Immunol Today* 20:203-207.
40. **Vossen MT, Westerhout EM, Soderberg-Naucler C, Wiertz EJ** (2002) Viral immune evasion: a masterpiece of evolution. *Immunogenetics* 54:527-542.
41. Jones TR, Wiertz EJ, Sun L, Fish KN, Nelson JA, Ploegh HL (1996) Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. *Proc Natl Acad Sci USA* 93:11327-11333.
42. **Park B, Kim Y, Shin J, Lee S, Cho K, Fruh K, Lee S, Ahn K** (2004) Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. *Immunity* 20:71-85.
43. **Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, Ploegh HL** (1996) The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. *Cell* 84:769-779.
44. **Barel MT, Rensing M, Pizzato N, van Leeuwen D, Le Bouteiller P, Lenfant F, Wiertz EJ** (2003) Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation. *J Immunol* 171:6757-6765.
45. **Barel MT, Pizzato N, van Leeuwen D, Bouteiller PL, Wiertz EJ, Lenfant F** (2003) Amino acid composition of alpha1/alpha2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation. *Eur J Immunol* 33:1707-1716.
46. **Hicklin DJ, Marincola FM, Ferrone S** (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. *Mol Med Today* 5:178-186.
47. **Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S** (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. *Adv Immunol* 74:181-273.
48. **Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, Cerundolo V, Man S** (2001) Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. *J Immunol* 167:5420-5428.
49. **van Hall T, Wolpert EZ, Van Veelen P, Laban S, van der Veer M, Roseboom M, Bres S, Grufman P, de Ru A, Meiring H, de Jong A, Franken K, Teixeira A, Valentijn R, Drijfhout JW, Koning F, Camps M, Ossendorp F, Karre K, Ljunggren HG, Melief CJ, Offringa R** (2006) Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. *Nat Med* 12:417-424.

